Humacyte Inc (HUMA)vsEli Lilly and Company (LLY)
HUMA
Humacyte Inc
$0.57
+0.09%
HEALTHCARE · Cap: $165.73M
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 3755959% more annual revenue ($79.67B vs $2.12M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
HUMA
Avoid24
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.9%
Fair Value
$2.52
Current Price
$0.57
$1.95 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.9% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -839.6% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
The strongest argument for HUMA centers on Revenue Growth. Revenue growth of 34.9% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 2.12 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
HUMA profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.47 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 24/100), backed by strong 33.5% margins and 47.7% revenue growth. HUMA offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?